- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
BridgeBio Oncology Therapeutics, Inc.(BBOT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BBOT
11/13/2026: BBOT (1-star) is currently NOT-A-BUY. Pass it for now.
BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biotechnology company developing precision small-molecule therapies for RAS-driven and PI3Kα-driven cancers. Its core strengths lie in a wholly owned pipeline featuring differentiated candidates like BBO-8520 and BBO-11818 designed to tackle drug resistance. The primary investment story centers on upcoming clinical data readouts and strategic combination trials that could validate its targeted oncology approach. However, the company faces substantial risks, including zero commercial revenues, high clinical attrition rates, and intense competition from well-funded peers. This stock suits growth-oriented investors with a high risk tolerance who are comfortable with binary clinical milestones and capital volatility.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Offers high-growth potential driven by novel oncology pipeline readouts, tempered by early-stage clinical risks. |
| Momentum investor | Strong fit while signal remains positive | Stock price can experience sharp momentum shifts around major clinical data catalysts and trial updates. |
| Value investor | Weak fit | Lacks commercial revenue, earnings, or traditional valuation metrics. |
| Dividend investor | Weak fit | The company pays no dividends and reinvests all capital into clinical programs. |
| Low-risk investor | Weak fit | High binary clinical trial risk and share price volatility make it unsuitable for conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotechnology stocks frequently experience dramatic price swings based on trial outcomes and market conditions. |
| Valuation risk | High | Valuation is entirely speculative based on future pipeline potential rather than current cash flows or earnings. |
| Competition risk (KRAS and precision oncology competitors) | Medium / high | Competing firms developing alternative targeted therapies could outpace or outperform BBOT's pipeline assets. |
| Business quality | Medium | The company features specialized scientific talent and promising intellectual property, but lacks a commercial commercialized franchise. |
| Dividend income | Low / none | No dividend is paid or expected in the near term. |
| Execution risk | High | Success depends entirely on clinical trial execution, regulatory clearance, and effective management of capital resources. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 171.74M USD | Price to earnings Ratio 4.04 | 1Y Target Price 21 |
Price to earnings Ratio 4.04 | 1Y Target Price 21 | ||
Volume (30-day avg) 630.4K shares | Beta 0.85 | 52 Weeks Range 1.98 - 14.87 | Updated Date 11/15/2026 |
52 Weeks Range 1.98 - 14.87 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.53 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -38.2% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Therapeutics Development | Future commercialization or out-licensing of small-molecule oncology drugs targeting RAS and PI3Kα pathways. | The company currently generates zero revenue and relies on future drug approvals or partnerships to commercialize its pipeline. |
Valuation
Trailing PE 4.04 | Forward PE - | Enterprise Value -20.55M | Price to Sales(TTM) - |
Enterprise Value -20.55M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 80.25M | Shares Floating 35.85M |
Shares Outstanding 80.25M | Shares Floating 35.85M | ||
Percent Insiders 27.14 | Percent Institutions 76.62 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

